Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | TRPM4 | Q8TD43 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | G6PD | P11413 | 1/20 | 0.65 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914622 | 0.88 | TRPM4 (0.64) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL4293534 | 0.88 | MAPT (0.69) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL4908222 | 0.88 | MAPT (0.71) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL4912967 | 0.87 | TRPM4 (0.77) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL4650386 | 0.87 | POLB (0.64) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL4096488 | 0.86 | MEN1 (0.64) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL4910731 | 0.85 | TRPM4 (0.64) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL31612238 | 0.85 | TRPM4 (1.00) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL34476055 | 0.85 | TRPM4 (1.00) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL4651368 | 0.85 | POLB (0.62) | MEN1KMT2AKDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | claimed |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | claimed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | claimed |
| WO-2008004798-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-01-10 | — | — | WO | claimed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | claimed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | claimed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-7408078-B2 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | WYETH (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2008004798-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-01-10 | — | — | WO | disclosed |
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | VIROPHARMA INCORPORATED | 2005-01-06 | — | — | US | disclosed |
| WO-2004091724-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004192-A1 | Anthranilic acid derivatives useful in treating infection with hepatitis C virus | HCCS, ALAD, HAVCR2 | MEN1 3867/4885KMT2A 1394/4885KDM4E 2214/4885 |
| US-20080269333-A1 | ANTHRANILIC ACID DERIVATIVES USEFUL IN TREATING INFECTION WITH HEPATITIS C VIRUS | HCCS, ALAD, HAVCR2 | MEN1 3867/4885KMT2A 1394/4885KDM4E 2214/4885 |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | MEN1 3620/4885KMT2A 1390/4885KDM4E 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.